Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Swiss National Bank

Swiss National Bank boosted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) by 2.6% in the fourth quarter, HoldingsChannel reports. The firm owned 131,300 shares of the company’s stock after purchasing an additional 3,300 shares during the quarter. Swiss National Bank’s holdings in Travere Therapeutics were worth $2,761,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Armistice Capital LLC raised its stake in Travere Therapeutics by 9.7% during the 3rd quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock valued at $143,799,000 after acquiring an additional 516,000 shares in the last quarter. State Street Corp raised its stake in Travere Therapeutics by 21.9% during the 2nd quarter. State Street Corp now owns 3,607,165 shares of the company’s stock valued at $87,402,000 after acquiring an additional 647,804 shares in the last quarter. Vanguard Group Inc. raised its stake in Travere Therapeutics by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,381,610 shares of the company’s stock valued at $83,323,000 after acquiring an additional 50,791 shares in the last quarter. Renaissance Technologies LLC raised its stake in Travere Therapeutics by 30.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,357,322 shares of the company’s stock valued at $34,978,000 after acquiring an additional 317,400 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Travere Therapeutics by 3.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,099,058 shares of the company’s stock valued at $28,321,000 after acquiring an additional 40,555 shares in the last quarter.

Travere Therapeutics Stock Up 0.2 %

Shares of Travere Therapeutics stock opened at $16.98 on Wednesday. The stock’s fifty day moving average is $19.68 and its 200-day moving average is $20.33. The firm has a market capitalization of $1.27 billion, a PE ratio of -3.82 and a beta of 0.46. The company has a quick ratio of 4.58, a current ratio of 4.63 and a debt-to-equity ratio of 1.99. Travere Therapeutics, Inc. has a 12-month low of $14.51 and a 12-month high of $29.14.

Travere Therapeutics (NASDAQ:TVTX – Get Rating) last announced its earnings results on Thursday, February 23rd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.01. The company had revenue of $55.87 million for the quarter, compared to analyst estimates of $54.80 million. Travere Therapeutics had a negative return on equity of 236.09% and a negative net margin of 130.98%. Equities analysts anticipate that Travere Therapeutics, Inc. will post -4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TVTX. TD Cowen began coverage on Travere Therapeutics in a research note on Monday. They set an “outperform” rating and a $30.00 target price on the stock. Evercore ISI cut their target price on Travere Therapeutics from $36.00 to $26.00 in a research note on Tuesday, May 2nd. Wedbush dropped their price objective on Travere Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a research note on Monday, April 17th. Barclays dropped their price objective on Travere Therapeutics from $37.00 to $31.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 21st. Finally, Bank of America dropped their price objective on Travere Therapeutics from $52.00 to $39.00 in a research note on Tuesday, May 2nd. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $29.85.

Travere Therapeutics Profile

(Get Rating)

Travere Therapeutics, Inc is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm’s products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.